Crafting CAR Tregs

Manufacturing process is key ingredient to TxCell’s CAR Treg therapy

TxCell S.A. (Euronext:TXCL) thinks it has cracked the code on building CAR Tregs without running into the manufacturing challenges that can compromise the cells’ immunosuppressive function. The company presented data on their manufacturing process at the CAR-TCR Summit Europe meeting last month and plans to submit an IND

Read the full 481 word article

User Sign In